| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-07-25 | Biofocus, a Galapagos Company (UK - Belgium) Activiomics (UK) | TIQUAS (Targeted In-depth QUAntification of cell Signaling - proteomics services for identification of novel targets for drug discovery and biomarkers for diagnostics) | collaboration |
Services contract | ||
| 2012-07-24 | Suppremol (Germany) University Hospital of Regensburg (Germany) | SM401 (humanized anti-IL-3 monoclonal antibody) | rheumatoid arthritis | licensing |
Autoimmune diseases - Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2012-07-23 | Boehringer Ingelheim (Germany) Funxional Therapeutics (UK) | FX125L compound and somatotaxin programm | inflammation, inflammatory diseases | product acquisition |
Inflammatory diseases | Product acquisition |
| 2012-07-19 | Baxter (USA) Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation) (The Netherlands) | fractionated plasma | manufacturing |
Hematologic diseases - Genetic diseases - Rare diseases - Immunological diseases | Production agreement | |
| 2012-07-19 | Cambridge Research Biochemicals (UK) LI-COR Biosciences (USA) | near-infrared dye-labelled peptides | licensing |
Licensing agreement | ||
| 2012-07-18 | Curetis (Germany) Advanced Technology Company K.S.C (Kuwait) | Unyvero™ solution | infectious diseases | distribution |
Infectious diseases | Distribution agreement |
| 2012-07-18 | Synthon (The Netherlands) Amgen (USA) Watson Pharmaceuticals (USA) | trastuzumab, being developed as a biosimilar to Herceptin® | breast cancer, gastric cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2012-07-18 | Sanofi (France) Brigham and Women's Hospital (USA) | immunomodulatory approach to treat type 1 diabetes | type 1 diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2012-07-18 | Pluristem Therapeutics (Israel) CPC Clinical Research (USA) | services related to enrolling and sustaining clinical site for a Phase II study using PLX-PAD cells for the treatment of intermittent claudication | intermittent claudication | clinical research |
Cardiovascular diseases | Clinical research agreement |
| 2012-07-17 | Royal DSM (The Netherlands) RECEPTA Biopharma (Brazil) | undisclosed Recepta BioPharma antibody | production |
Production agreement | ||
| 2012-07-17 | Vivalis (France) Merial, a Sanofi company (France) | EB66® cell line | licensing |
Veterinary medicine | Licensing agreement | |
| 2012-07-17 | 4SC AG (Germany) Crelux (Germany) Ribological (Germany) | compound screening to identify and optimise new and more effective anti-cancer compounds | various cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2012-07-16 | ImmunoGenes (Switzerland-Hungary) NYU’s Feske Lab (USA) | therapeutic antibodies | autoimmune diseases, infectious diseases | R&D |
Autoimmune diseases - Infectious diseases | R&D agreement |
| 2012-07-16 | ImmunoGenes (Switzerland - Hungary) NYU School of Medicine (USA) | therapeutic antibodies | R&D |
Autoimmune diseases - Infectious diseases | R&D agreement | |
| 2012-07-12 | AstraZeneca (UK) Link Medicine Corporation (USA) | small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy | pipeline acquisition |
Neurodegenerative diseases | Pipeline acquisition | |
| 2012-07-12 | Benitec Biopharma (Australia) Genable Technologies (Ireland) | ddRNAi technology | retinitis pigmentosa | licensing |
Rare diseases - Genetic diseases - Ophtalmological diseases | Licensing agreement |
| 2012-07-10 | Janssen Pharmaceuticals J&J (USA) - CureBeta (initiative was established by Harvard, the Howard Hughes Medical Institute (HHMI), and Evotec in 2011 to leverage the assets and expertise in industry and academia to identify and develop disease-state modifying therapeutic targets) (Germany - USA) | portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells | diabetes | licensing |
Metabolic diseases | Licensing agreement |
| 2012-07-10 | tebu-bio (France) Smartox Biotechnology (France) | synthetic peptides originating from venomous animals such as spiders, cone snails and scorpions | distribution |
Distribution agreement | ||
| 2012-07-10 | Boehringer Ingelheim (Germany) Healthrageous (USA) | digital diabetes self-management program | type 2 diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2012-07-09 | Actelion (Switzerland) Auxilium Pharmaceuticals (USA) | Xiapex®(EU)/ Xiaflex® (USA) (collagenase clostridium histolyticum) | Dupuytren's contracture, Peyronie's disease | development |
Inflammatory diseases | Development agreement |
